Lacouture ME - Search Results

1

Immune-related cutaneous adverse events due to checkpoint inhibitors.

Wang E, Kraehenbuehl L, Ketosugbo K, Kern JA, Lacouture ME, Leung DYM. Wang E, et al. Among authors: lacouture me. Ann Allergy Asthma Immunol. 2021 Jun;126(6):613-622. doi: 10.1016/j.anai.2021.02.009. Epub 2021 Feb 17. Ann Allergy Asthma Immunol. 2021. PMID: 33609771 Free PMC article. Review.

2

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.

Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x. Int J Dermatol. 2011. PMID: 21244375 Review.

3

The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.

Balagula Y, Rosen ST, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. J Am Acad Dermatol. 2011 Sep;65(3):624-635. doi: 10.1016/j.jaad.2010.06.051. Epub 2011 Jul 20. J Am Acad Dermatol. 2011. PMID: 21777992 Review.

4

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

Lacouture ME, O'Reilly K, Rosen N, Solit DB. Lacouture ME, et al. J Clin Oncol. 2012 Jan 20;30(3):329-30. doi: 10.1200/JCO.2011.38.2895. Epub 2011 Nov 7. J Clin Oncol. 2012. PMID: 22067405 No abstract available.

5

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, Feldman DR, Konner JA, Reidy-Lagunes D, Myskowski PL, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. Cancer. 2012 Oct 15;118(20):5078-83. doi: 10.1002/cncr.27505. Epub 2012 Mar 21. Cancer. 2012. PMID: 22437824 Free article.

6

Dermatological adverse events from BRAF inhibitors: a growing problem.

Belum VR, Fischer A, Choi JN, Lacouture ME. Belum VR, et al. Among authors: lacouture me. Curr Oncol Rep. 2013 Jun;15(3):249-59. doi: 10.1007/s11912-013-0308-6. Curr Oncol Rep. 2013. PMID: 23463215 Review.

7

Ipilimumab in patients with cancer and the management of dermatologic adverse events.

Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Lacouture ME, et al. J Am Acad Dermatol. 2014 Jul;71(1):161-9. doi: 10.1016/j.jaad.2014.02.035. Epub 2014 Apr 24. J Am Acad Dermatol. 2014. PMID: 24767731 Review.

8

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.

Lacouture ME, Ciccolini K, Kloos RT, Agulnik M. Lacouture ME, et al. Thyroid. 2014 Sep;24(9):1329-40. doi: 10.1089/thy.2013.0700. Epub 2014 Jul 15. Thyroid. 2014. PMID: 24902006 Free PMC article. Review.

9

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J. Lacouture ME, et al. Cancer Immunol Immunother. 2015 Apr;64(4):437-46. doi: 10.1007/s00262-015-1653-0. Epub 2015 Jan 13. Cancer Immunol Immunother. 2015. PMID: 25579378 Free PMC article. Clinical Trial.

10

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.

Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME. Belum VR, et al. Among authors: lacouture me. Pediatr Blood Cancer. 2015 May;62(5):798-806. doi: 10.1002/pbc.25429. Epub 2015 Feb 12. Pediatr Blood Cancer. 2015. PMID: 25683226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

317 results

Search Page